Table 1.
Characteristics of the included studies
| First author | Year | Trials’ name |
Patients (n) | Median age, year (range) |
Median follow-up, month (range) |
FAB type | Experiment group (CRi) |
Control group (CRi) |
Experiment(n)/ Control(n) |
|---|---|---|---|---|---|---|---|---|---|
| Marilyn L. Slovak | 2000 | E3489/S9034 | 129 | 39 (16–55) | 60 (NA) | M0-M6 |
Allo-SCT† (CR1) |
Auto-SCT (CR1) |
66/63 |
|
Stefan Suciu |
2003 | EORTC/GIMEMAAML−10 | 288 |
T: 33 (15–45) C: 35 (15–45) |
48 (NA) | M0-M7 |
Allo-SCT† (donor, CR1) |
Auto-SCT (no donor, CR1) |
111/177 |
|
Eric Jourdan |
2005 | BGMT | 299 |
T: 34 (15–45) C: 33.5 (15–45) |
114 (29–222) | M0-M7 |
Allo-SCT† (donor, CR1) |
Auto-SCT (no donor, CR1) |
110/189 |
| Markus Pfirrmann | 2012 | AML96 | 260 | 46 (15–60) | 36 (NA) |
M0-M2, M4-M7 |
Allo-SCT† (CR) |
Auto-SCT (CR) |
117/143 |
| Markus Pfirrmann* | 2012 | AML2003 | 141 | 49 (39–55) | 36 (NA) | M0-M2 M4-M7 |
Allo-SCT† (CR) |
Auto-SCT (CR) |
109/32 |
|
Ki-Seong Eom |
2015 | NA | 59 | 36.0 (16–64) | 60.9 (50.0−71.9) | NA |
Allo-SCT‡ (CR1) |
Auto-SCT (CR1) |
30/29 |
|
Jia Chen |
2018 | NA | 195 |
T: 28 (16–42) C: 34 (24–45) |
33 (NA) | NA |
Haplo-SCT (CR1) |
Auto-SCT (CR1) |
107/88 |
|
Frederic Baron |
2020 |
EORTC/GIMEMA AML−10 |
497 |
T: 33 (15–45) C: 35 (15–45) |
132 (NA) | M0-M7 |
Allo-SCT† (donor, CR) |
Auto-SCT (no donor, CR) |
185/312 |
| Jean-Luc Harousseau | 1997 | GOELAM | 164 | 36 (15–50) | 62 (NA) | M0-M7 |
Auto-SCT (CR1) |
CT | 86/78 |
| Apostolia-Maria Tsimberidou | 2003 | AML8 | 34 | NA (15–50) | 55 (33–64) |
M0-M2, M4-M6 |
Auto-SCT (CR1) |
CT | 19/15 |
| Dimitri A. Breems | 2005 |
HOVON/ SAKK AML4 |
130 | 43 (NA) | 154 (NA) | M0-M6 |
Auto-SCT (CR1) |
CT | 66/64 |
|
Edo Vellenga |
2011 |
AML−29 AML−42 |
447 |
T: 49 (16–61) C: 47 (16–61) |
106 (13–177) | M0-M2 M4-M7 |
Auto-SCT (CR1) |
CT | 231/216 |
|
Romain Guieze |
2012 | GOELAMS LAM−2001 | 31 | 47 (18–60) | 86 (16–118) | M0-M2 M4-M7 |
Auto-SCT (CR1) |
CT | 21/10 |
|
Kensuke Usuki |
2012 | NA | 1212 |
T:48 (16–70) C:52 (16–70) |
50 (0.2–116 ) | M0-M2 M4-M7 |
Auto-SCT (CR1) |
CT | 75/1137 |
| Marie-Anne Hospital | 2014 |
ALFA−9801 ALFA−9802 LAM−2001 CBF−2006 |
67 | 43 (16–76) | 42 (NA) | NA |
Auto-SCT (CR2) |
CT | 18/49 |
|
Toshihiro Miyamoto |
2017 | NA | 87 |
T: 46.5 (18–63) C: 48 (19–64) |
T: 55.1 (3.7−147.9) C: 61.1 ( 4.0−142.0) |
M1, M2, M4, M5 |
Auto-SCT (CR1) |
CT | 42/45 |
|
Adriano Venditti |
2019 | GIMEMA AML1310 | 117 | 49 (18–60) | 28.8 (NA) | M0-M2 M4-M7 |
Auto-SCT (CR1) |
CT | 19/98 |
|
Eun‑Ji Choi |
2021 | NCT01050036 | 42 | 40 (19−60) | 55.2 (NA) | NA |
Auto-SCT (CR1) |
CT | 29/13 |
|
RF Schlenk |
2003 | AML HD93 | 73 | 46 (16–60) | 64 (NA) | M0-M2 M4-M7 |
Allo-SCT† (CR1) |
CT | 16/57 |
| Hisashi Sakamaki | 2010 | AML97 | 165 |
T: 37 (16–50) C: 36 (15–50) |
NA (3.1−105.8) | M0-M2 M4-M7 |
Allo-SCT† (donor, CR) |
CT (no donor) |
73/92 |
|
Xiao-Jun Huang |
2012 | NA | 122 |
T: 30 (16–47) C: 47 (15–60) |
19 ( 4–63) | M0-M2 M4-M7 |
Haplo-SCT (CR1) |
CT | 52/70 |
| Richard F. Schlenk | 2013 |
HOVON /SAKK AMLSG |
92 104 |
44 (16–60) | 62 (NA) | M0-M2 M4-M6 |
Auto-SCT Allo-SCT† (CR1) |
CT |
20/72 32/72 |
|
Hong-Hu Zhu |
2013 | AML05 | 69 | 33 (15–56) | 36 (6–83 ) | NA |
Allo-SCT£ (CR1) |
CT | 40/29 |
|
Matthias Stelljes |
2014 | AMLCG99 | 288 |
T:45 (16–59) C:46 (17–59) |
144 (NA) | M0-M2 M4-M7 |
Allo-SCT‡ (CR1) |
CT | 144/144 |
| K. Heidrich | 2017 |
AML2003 AML96 |
246 | 48 (39–55) | 72 (NA) | M0-M2 M4-M7 |
Allo-SCT‡ (CR) |
CT | 97/149 |
| Wasithep Limvorapitak | 2018 | NA | 190 | NA(18–65) | 104.4 (25.2−181.2) | NA |
Allo-SCT† Allo-SCT§ Auto-SCT (CR1) |
CT |
62/80 18/80 30/80 |
|
Meng Lv |
2018 | NA | 147 |
T:30 (16–58) C:44 (21–60) |
48.6 (36.1–88.5) | M0-M2 M4-M6 |
Haplo-SCT (CR1) |
CT | 78/69 |
|
Adam Folta |
2019 | NA | 116 | 54 (19–72) | NA | M0-M2 M4-M7 |
Allo-SCT (NA) |
CT | 74/42 |
|
Nigel H. Russell |
2021 | AML16 | 728 | NA (60–70) | 60 (NA) | M0-M2 M4-M7 |
Allo-SCT‡ (CR) |
CT | 122/728 |
| Martin Bornhauser | 2023 | NCT01246752 | 143 |
T: 50.5 (19.0–60.0) C: 51.0 (24.0–60.0) |
50 (48–66) | M0-M2 M4-M7 |
Allo-SCT‡ (CR1) |
CT | 76/67 |
Note Allo-SCT†: HLA-identical sibling donor; Allo-SCT‡: HLA-matched donor; Allo-SCT£: The donor of more than 50% patients in the group was HLA-matched; Allo-SCT§: Non-related donors, including HLA-mismatched and matched; Markus Pfirrmann *:Data sourced from supplementary materials; Jean-Luc Harousseau 1997: The non-high-risk patients accounted for 88%; Dimitri A. Breems 2005: The non-high-risk patients accounted for 92%; Stefan Suciu 2003: The study was divided into the donor group and the non-donor group, but over 70% patients of the donor group underwent allo-SCT, and over 60% patients of the non-donor group underwent auto-SCT; Eric Jourdan 2005: 94% of patients in the donor group underwent allo-SCT, and 62% of patients in the non-donor group received auto-SCT; Hisashi Sakamaki 2010: More than half of patients in the donor group underwent allo-SCT, with over 87% patients having an intermediate-risk classification Frederic Baron 2020: 71% of patients in the donor group underwent allo-SCT, and 53% of patients in the non-donor group received auto-SCT; Abbreviation T, treatment group; C, control group; NA, not available; CT, chemotherapy; CR, complete remission; allo-SCT, allogenic stem cell transplantation; auto-SCT, autologous stem cell transplantation; haplo-SCT, haploidentical stem cell transplantation; FAB, French-American-British